Treatment exposure
Approximately one third of patients were able to stay on YONDELIS® 6 cycles or longer
1 out of 3 (34%) patients in the YONDELIS® group received 6 or more cycles of treatment, and 1 out of 10 (10%) received 12 or more cycles.1
Cumulative treatment cycles received (all treated patients)2 | ||
---|---|---|
Treatment cycles received |
YONDELIS® (n=340) % (n) |
Dacarbazine (n=155) % (n) |
≥3 | 57.1 (194) | 43.2 (67) |
≥6 | 34.4 (117) | 17.4 (27) |
≥9 | 17.4 (59) | 5.2 (8) |
≥12 | 10.3 (35) | 1.9 (3) |
Cumulative treatment cycles received (All treated patients)2 | |
---|---|
Treatment cycles received |
YONDELIS® (n=340) % (n) |
≥3 | 57.1 (194) |
≥6 | 34.4 (117) |
≥9 | 17.4 (59) |
≥12 | 10.3 (35) |
Treatment cycles received |
Dacarbazine (n=155) % (n) |
≥3 | 43.2 (67) |
≥6 | 17.4 (27) |
≥9 | 5.2 (8) |
≥12 | 1.9 (3) |